A study published in The EMBO Journal opens new perspectives to better understand how the molecular mechanisms involved in regenerative medicine work.
Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma
Data presented at the 2023 American Society of Hematology (ASH) annual meeting demonstrated that adding the anti-CD38 antibody daratumumab (Darzalex) to bortezomib (Velcade), lenalidomide (Revlimid),